TD Asset Management Inc Grows Position in Bio-Rad Laboratories, Inc. $BIO

TD Asset Management Inc increased its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 461.0% in the third quarter, Holdings Channel.com reports. The fund owned 8,988 shares of the medical research company’s stock after purchasing an additional 7,386 shares during the period. TD Asset Management Inc’s holdings in Bio-Rad Laboratories were worth $2,520,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Royal Bank of Canada lifted its stake in Bio-Rad Laboratories by 25.2% in the 1st quarter. Royal Bank of Canada now owns 30,310 shares of the medical research company’s stock worth $7,382,000 after purchasing an additional 6,100 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Bio-Rad Laboratories by 45.6% in the first quarter. Goldman Sachs Group Inc. now owns 105,006 shares of the medical research company’s stock worth $25,575,000 after purchasing an additional 32,874 shares during the last quarter. Empowered Funds LLC lifted its position in shares of Bio-Rad Laboratories by 14.8% in the first quarter. Empowered Funds LLC now owns 1,547 shares of the medical research company’s stock worth $377,000 after buying an additional 199 shares in the last quarter. Jane Street Group LLC lifted its position in shares of Bio-Rad Laboratories by 95.3% in the first quarter. Jane Street Group LLC now owns 37,383 shares of the medical research company’s stock worth $9,105,000 after buying an additional 18,239 shares in the last quarter. Finally, Teacher Retirement System of Texas boosted its stake in Bio-Rad Laboratories by 19.7% during the second quarter. Teacher Retirement System of Texas now owns 3,409 shares of the medical research company’s stock valued at $823,000 after buying an additional 562 shares during the last quarter. 65.24% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have issued reports on BIO shares. Wall Street Zen downgraded Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Bio-Rad Laboratories in a report on Monday, December 29th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $358.50.

Bio-Rad Laboratories Stock Up 1.7%

Shares of BIO opened at $284.83 on Thursday. The company has a quick ratio of 4.19, a current ratio of 5.62 and a debt-to-equity ratio of 0.16. The business has a fifty day moving average of $296.91 and a 200 day moving average of $301.34. The company has a market cap of $7.69 billion, a PE ratio of 10.21 and a beta of 1.18. Bio-Rad Laboratories, Inc. has a 52-week low of $211.43 and a 52-week high of $343.12.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings data on Thursday, February 12th. The medical research company reported $2.51 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.57 by ($0.06). Bio-Rad Laboratories had a return on equity of 3.86% and a net margin of 29.42%.The firm had revenue of $693.20 million during the quarter, compared to the consensus estimate of $694.64 million. During the same period in the previous year, the business earned $2.90 EPS. The firm’s revenue for the quarter was up 3.9% on a year-over-year basis. On average, sell-side analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.